SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results.

Business Highlights

• Collaboration agreement for zevor-cel commercialization in mainland China...